Version history

{
  "question": "Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determining donanemab cessation thresholds?",
  "domain": "neurodegeneration",
  "status": "completed",
  "gap_id": "gap-debate-20260417-033134-20519caa",
  "metadata": {
    "world_model_ranking": {
      "formula": "0.30*kg_impact + 0.25*hyp_quality + 0.20*debate_depth + 0.15*gap_addressed + 0.10*research_depth",
      "task_id": "ce3182a7-f33b-44b6-9dd8-ef784cf9e231",
      "weights": {
        "kg_impact": 0.3,
        "hyp_quality": 0.25,
        "debate_depth": 0.2,
        "gap_addressed": 0.15,
        "research_depth": 0.1
      },
      "scored_at": "2026-04-28T01:28:15.062969+00:00",
      "dimension_notes": {
        "kg_impact": "kg_impact_score=0.0 (no direct edge tracking; = 0)",
        "hyp_quality": "avg_composite_score=0.4264 from 7 hypotheses",
        "debate_depth": "avg_debate_quality=1.000 × min(debate_count=1 / 3, 1) = 0.3333",
        "gap_addressed": "gap_id='gap-debate-20260417-033134-20519caa'",
        "research_depth": "total_hyps_generated=49"
      },
      "dimension_scores": {
        "kg_impact": 0,
        "hyp_quality": 0.426429,
        "debate_depth": 0.333333,
        "gap_addressed": 1,
        "research_depth": 1
      },
      "world_model_rank": 0.423274
    }
  },
  "completed_at": "2026-04-26T15:50:49.612188-07:00",
  "report_url": "/analyses/SDA-2026-04-26-gap-debate-20260417-033134-20519caa"
}

{
  "question": "Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determining donanemab cessation thresholds?",
  "domain": "neurodegeneration",
  "status": "completed",
  "gap_id": "gap-debate-20260417-033134-20519caa",
  "completed_at": "2026-04-26T15:50:49.612188-07:00",
  "report_url": "/analyses/SDA-2026-04-26-gap-debate-20260417-033134-20519caa"
}

{
  "question": "Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determining donanemab cessation thresholds?",
  "domain": "neurodegeneration",
  "status": "completed",
  "gap_id": "gap-debate-20260417-033134-20519caa",
  "completed_at": "2026-04-26T15:50:49.612188-07:00",
  "report_url": "/analyses/SDA-2026-04-26-gap-debate-20260417-033134-20519caa"
}

{
  "question": "Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determining donanemab cessation thresholds?",
  "domain": "neurodegeneration",
  "status": "completed",
  "gap_id": "gap-debate-20260417-033134-20519caa",
  "completed_at": "2026-04-26T15:50:49.612188-07:00"
}